![](/img/cover-not-exists.png)
Efficacy of Continuous, Daily, Oral, Ultra-low-dose 200 mg Acyclovir to Prevent Herpes Zoster Events Among Bortezomib-treated Patients: A Report From Retrospective Study
Aoki, T., Nishiyama, T., Imahashi, N., Kitamura, K.Volume:
41
Language:
english
Journal:
Japanese Journal of Clinical Oncology
DOI:
10.1093/jjco/hyr063
Date:
July, 2011
File:
PDF, 100 KB
english, 2011